Clinical Study
To observe the clinical efficacy of Huajian-Badu membrane in the treatment of moderate and severe cancer pain
Liu Zhao, Li Xiaojiang, Zhang Hong, Mou Ruiyu, Guo Shanqi, Jia Yingjie
Published 2019-03-30
Cite as Int J Trad Chin Med, 2019,41(3): 234-237. DOI: 10.3760/cma.j.issn.1673-4246.2019.03.006
Abstract
ObjectiveTo observe the clinical efficacy of Huajian-Badu membrane in the treatment of moderate and severe cancer pain.
MethodsThe 80 malignant tumor patients with moderate to severe cancer pain from January 2016 to June 2017 in Tianjin University of Traditional Chinese Medicine First Teaching Hospital were recruited and randomly divided into the observation group and the control group, each of 40 cases. The control group were treated with Oxycodone Hydrochloride Prolonged-release Tablets, while the treatment group were treated with Huajian-Badu membrane on the basis of the treatment in control group. The pain relief, pain frequency, morphine consumption and quality of life (Karnofsky score), adverse reaction were evaluated between two groups before and after treatment.
ResultsCompared with the control group, the total efficiency in the observation group was significantly higher (95.0% vs. 80.0%, χ2=4.114, P=0.043). The frequency of breakthrough pain of two groups increased on the seventh and fourteenth treatment days(0.3 ± 0.6 times vs. 0.8 ± 0.7 times, t=-3.430 and 0.4 ± 0.6 times vs. 0.9 ± 0.8 times, t=-3.162), but the number of outbreaks of pain in the observation group significantly less than the control group (P<0.05 or P<0.01). The morphine injection dosage increased on the seventh and fourteenth treatment days (3.01 ± 4.28 g vs. 5.62 ± 6.37 g, t=-2.151 and 3.21 ± 4.32 g vs. 7.84 ± 7.76 g, t=-3.297), but the amount of the observtation group was significantly lower than that of control group (P<0.05 or P<0.01). The KPS score in the observation group increased significantly, and significantly higher than the control group on the seventh and fourteenth treatment days (73.0 ± 15.0 vs. 66.0 ± 12.0, t=2.305 and 77.0 ± 13.0 vs. 70.0 ± 15.0, t=2.230, P<0.05). The adverse reaction rate of the control group was 25%, while the the observation group was 20%. The difference between two groups was significant (χ2=0.287, P=0.592).
ConclusionsThe Huajian-Badu membrane combined Oxycodone Hydrochloride Prolonged-release Tablets can improve the total effective rate of pain relief, reduce the number of outbreaks, reduce morphine consumption, improve patient KPS score of the patients with cancer pain.
Key words:
Cancer pain; Huajian-Badu membrane; Oxycodone Hydrochloride Prolonged-release tablets; Morphine; Analgesics (TCD); Drug-related side effects and adverse reactions
Contributor Information
Liu Zhao
Department of Oncology, the First Teaching Hospital of Tianjin University of Chinese Medicine in Oncology, Tianjin 300381, China
Li Xiaojiang
Zhang Hong
Mou Ruiyu
Guo Shanqi
Jia Yingjie
